General Counsel, Form 4 Reporting, and Corporate Immunity to Opportunistic Insider Trading
SSRN Electronic Journal · 2026
DOI: 10.2139/ssrn.6685338 ↗Kurz gefasst
Fachartikel in der Zeitschrift SSRN Electronic Journal, 2026. Verfasst von Alan D. Jagolinzer und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Corporate insiders can profit from privately informed equity trades, absent proper governance. Prior research explores whether regulation or corporate governance mitigates exploitive trading, and some studies show efficacy with General Counsel (GC) approval. These studies do not, however, observe how the GC governs trading, leaving unclear the degree of scrutiny. We identify trade-level scrutiny of insiders' transactions by exploiting the signature line contained in SEC Form 4 filings. For 462 health-sector firms, before and during the COVID pandemic, we collect data on the identity of Form 4 signatories, to identify transactions signed and reported to the SEC by the GC. We highlight this sample because healthcare insiders possessed highly exploitable private information during the pandemic, and governance systems likely came under strain. Our empirical tests show that during the COVID crisis, healthcare insiders earned substantial profits in trades where the GC did not sign the Form 4 filings, even within firms where the GC signed other trades. Collectively, our results suggest that GC scrutiny of individual insider transactions offers highly efficacious governance.
Zitieren
APA
Jagolinzer, A. D., Pierce, A. T., & Ryu, P. W. (2026). General Counsel, Form 4 Reporting, and Corporate Immunity to Opportunistic Insider Trading. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.6685338
Vancouver
Jagolinzer AD, Pierce AT, Ryu PW. General Counsel, Form 4 Reporting, and Corporate Immunity to Opportunistic Insider Trading. SSRN Electronic Journal. 2026. doi:10.2139/ssrn.6685338
BibTeX
@article{Jagolinzer2026,
author = {Jagolinzer, Alan D. and Pierce, Andrew T. and Ryu, Patrick W.},
title = {General Counsel, Form 4 Reporting, and Corporate Immunity to Opportunistic Insider Trading},
journal = {SSRN Electronic Journal},
year = {2026},
doi = {10.2139/ssrn.6685338}
}
EUVIMED